This study focused on improving the gemcitabine sensitivity in pancreatic ductal adenocarcinoma (PDAC) by targeting ATF4/HSPA5/GPX4 axis, while the exact molecular mechanism was not deeply studied. This evidence concerns the gene ATF4 and pancreatic ductal adenocarcinoma.